We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

435 hedge funds and large institutions have $5.66B invested in Teva Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 130 increasing their positions, 133 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more call options, than puts

Call options by funds: $277M | Put options by funds: $174M

51% more capital invested

Capital invested by funds: $3.74B → $5.66B (+$1.92B)

46% more funds holding in top 10

Funds holding in top 10: 13 → 19 (+6)

29% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 42

5.25% more ownership

Funds ownership: 44.22% → 49.48% (+5.3%)

2% more funds holding

Funds holding: 428 → 435 (+7)

2% less repeat investments, than reductions

Existing positions increased: 130 | Existing positions reduced: 133

Holders
435
Holders Change
+7
Holders Change %
+1.64%
% of All Funds
6.9%
Holding in Top 10
19
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+46.15%
% of All Funds
0.3%
New
54
Increased
130
Reduced
133
Closed
42
Calls
$277M
Puts
$174M
Net Calls
+$103M
Net Calls Change
+$86.8M

Top Buyers

1
HIIFS
Harel Insurance Investments & Financial Services
Israel
+$258M
2
SPC
Slate Path Capital
New York
+$106M
3
LIM
Lingotto Investment Management
United Kingdom
+$89.7M
4
SSM
Sound Shore Management
Connecticut
+$73.8M
5
IAM
Ion Asset Management
Israel
+$53.6M

Top Sellers

1
Norges Bank
Norges Bank
Norway
-$94M
2
Millennium Management
Millennium Management
New York
-$38.8M
3
Jane Street
Jane Street
New York
-$36.8M
4
Renaissance Technologies
Renaissance Technologies
New York
-$23.5M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$23.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$416M +$4.6M +493,488 +1%
IAM
2
Ion Asset Management
Israel
$396M +$53.6M +5,759,512 +17%
PF
3
Phoenix Financial
Israel
$352M +$7.25M +778,282 +2%
LIM
4
Lingotto Investment Management
United Kingdom
$345M +$89.7M +9,636,595 +40%
CI
5
Clal Insurance
Israel
$312M -$9.31M -1,000,000 -3%
MMH
6
Menora Mivtachim Holdings
Israel
$287M +$14.4M +1,550,184 +6%
HIIFS
7
Harel Insurance Investments & Financial Services
Israel
$283M +$258M +27,696,340 +184,642%
MIFH
8
Migdal Insurance & Financial Holdings
Israel
$276M +$31.8M +3,413,100 +14%
SPC
9
Slate Path Capital
New York
$243M +$106M +11,407,000 +92%
RCMNY
10
Rubric Capital Management (New York)
New York
$194M +$2.62M +281,638 +2%
State Street
11
State Street
Massachusetts
$163M +$4.02M +431,999 +3%
CCM
12
Camber Capital Management
Massachusetts
$104M +$15.4M +1,650,000 +19%
Capital International Investors
13
Capital International Investors
California
$102M -$49.7K -5,340 -0.1%
Millennium Management
14
Millennium Management
New York
$101M -$38.8M -4,172,267 -30%
ACM
15
Abrams Capital Management
Massachusetts
$81.3M – – –
SSM
16
Sound Shore Management
Connecticut
$80.8M +$73.8M +7,920,712 New
A
17
AustralianSuper
Australia
$77.6M +$6.18M +664,152 +10%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$76.2M +$3.25M +349,180 +5%
EP
19
Eversept Partners
New York
$70.9M -$6.67M -715,959 -9%
Alyeska Investment Group
20
Alyeska Investment Group
Illinois
$65.9M +$46.2M +4,962,576 +331%
SCM
21
Soleus Capital Management
Connecticut
$61.7M +$16.8M +1,802,164 +42%
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$61.6M +$5.43M +582,945 +11%
Morgan Stanley
23
Morgan Stanley
New York
$59.2M -$10.6M -1,141,312 -16%
Holocene Advisors
24
Holocene Advisors
New York
$52.3M +$47.7M +5,122,773 New
Goldman Sachs
25
Goldman Sachs
New York
$45.3M -$1.03M -110,540 -2%
1
2 3 4 5

TEVA Hedge Fund Activity: Q3 2023 in Review

435 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2023, worth a combined $5.66B — up 51% from $3.74B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new TEVA positions and 42 closed out — a net gain of 12 holders — while 130 added to existing stakes and 133 trimmed.

The largest buyer was Harel Insurance Investments & Financial Services, adding an estimated $258M. The largest seller was Norges Bank, cutting an estimated $94M.

  • 435 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2023, up from 428 in Q2 2023.
  • Funds reported $5.66B of Teva Pharmaceuticals stock for Q3 2023, up 51% quarter-over-quarter.
  • 54 funds opened new Teva Pharmaceuticals positions in Q3 2023 and 42 closed out, a net change of +12 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2023 was Harel Insurance Investments & Financial Services, an estimated $258M added.
  • The largest Teva Pharmaceuticals seller in Q3 2023 was Norges Bank, an estimated $94M sold.

Based on aggregated 13F filings for Q3 2023.